- Home
- KMDA vs ENGN Comparison
KMDA vs ENGN Comparison
Compare KMDA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KMDA | ENGN |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | Israel | Canada |
| Employees | 374 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.3M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KMDA | ENGN |
|---|---|---|
| Price | $6.97 | $7.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $13.00 | ★ $22.71 |
| AVG Volume (30 Days) | 66.9K | ★ 3.3M |
| Earning Date | 11-10-2025 | 12-18-2025 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 30.41 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $174,787,000.00 | N/A |
| Revenue This Year | $14.49 | N/A |
| Revenue Next Year | $10.12 | N/A |
| P/E Ratio | $19.14 | ★ N/A |
| Revenue Growth | ★ 10.36 | N/A |
| 52 Week Low | $5.54 | $2.65 |
| 52 Week High | $9.16 | $11.14 |
Technical Indicators
Market Signals| Indicator | KMDA | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | 55.40 |
| Support Level | $6.70 | $7.55 |
| Resistance Level | $6.83 | $8.36 |
| Average True Range (ATR) | 0.16 | 0.77 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 47.65 | 51.29 |
Price Performance
Historical ComparisonAbout KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.